| Literature DB >> 20563754 |
Maria A Rueger1,2,3, Mitra Ameli1,3, Hongfeng Li1, Alexandra Winkeler1,2, Benedikt Rueckriem4, Stefan Vollmar1, Norbert Galldiks1, Volker Hesselmann4, Cornel Fraefel1, Klaus Wienhard1, Wolf-Dieter Heiss1, Andreas H Jacobs5,6,7.
Abstract
The purpose of this study was to investigate the potential of 3'-deoxy-3'-[¹⁸F]fluorothymidine ([¹⁸F]FLT) positron emission tomography (PET) to detect early treatment responses in gliomas. Human glioma cells were stably transduced with genes yielding therapeutic activity, sorted for different levels of exogenous gene expression, and implanted subcutaneously into nude mice. Multimodality imaging during prodrug therapy included (a) magnetic resonance imaging, (b) PET with 9-(4-[¹⁸F]fluoro-3-hydroxymethylbutyl)guanine assessing exogenous gene expression, and (c) repeat [¹⁸F]FLT PET assessing antiproliferative therapeutic response. All stably transduced gliomas responded to therapy with significant reduction in tumor volume and [¹⁸F]FLT accumulation within 3 days after initiation of therapy. The change in [¹⁸F]FLT uptake before and after treatment correlated to volumetrically calculated growth rates. Therapeutic efficacy as monitored by [¹⁸F]FLT PET correlated to levels of therapeutic gene expression measured in vivo. Thus, [¹⁸F]FLT PET assesses early antiproliferative effects, making it a promising radiotracer for the development of novel treatments for glioma.Entities:
Mesh：
Substances：
Year: 2011 PMID： 20563754 DOI： 10.1007/s11307-010-0361-6
Source DB: PubMed Journal: Mol Imaging Biol ISSN： 1536-1632 Impact factor: 3.488